Adenosine deaminase (ADA) is an enzyme that converts adenosine, a signaling molecule found throughout the body, into inosine. This reaction is essential for preventing a toxic buildup of adenosine and its byproducts, particularly in immune cells. Without enough ADA activity, developing immune cells die before they mature, leaving the body unable to fight infections.
The Core Reaction
ADA’s primary job is straightforward: it removes an amino group from adenosine and replaces it with oxygen, turning adenosine into inosine. It also performs the same reaction on a closely related molecule called deoxyadenosine, converting it to deoxyinosine. Of these two substrates, ADA prefers adenosine, processing it at roughly twice the rate of deoxyadenosine. The reaction releases ammonia as a byproduct.
This conversion is part of the broader purine recycling pathway, which breaks down and recycles the building blocks of DNA and RNA. ADA sits at a critical junction in that pathway. By keeping adenosine and deoxyadenosine levels low, it prevents these molecules from accumulating to concentrations that damage cells.
The enzyme relies on a zinc ion at its active site to work. That zinc atom polarizes a water molecule, positioning it to attack the adenosine molecule at a precise spot on its ring structure. Humans have two forms of the enzyme, ADA1 and ADA2, both belonging to the zinc-dependent hydrolase family. Together, they regulate adenosine and inosine levels to support immune cell function, differentiation, and inflammatory responses.
Why Immune Cells Depend on It
Every cell in the body has some ADA, but immune cells need it most. Adenosine is a powerful extracellular signaling molecule that, at normal levels, helps regulate immune responses. When ADA is missing or severely reduced, three things go wrong simultaneously.
First, deoxyadenosine accumulates inside cells and gets converted into deoxyadenosine triphosphate (dATP). High dATP levels block an enzyme called ribonucleotide reductase, which cells need to synthesize and repair DNA. Rapidly dividing cells like lymphocytes are hit hardest. Second, excess deoxyadenosine permanently disables another enzyme involved in a chemical process called methylation, which developing T-cells in the thymus require to mature properly. Third, the buildup of adenosine outside cells disrupts the signaling pathways that coordinate normal immune responses.
Immature lymphocytes in the thymus are especially vulnerable. These cells die before they can develop into functioning T-cells, B-cells, or natural killer cells. The result is a near-complete collapse of the adaptive immune system.
ADA on the Cell Surface
ADA doesn’t only work inside cells. It also appears on the outer surface of T-cells, where it binds to a receptor protein called CD26. Research shows that when ADA latches onto CD26, it delivers a costimulatory signal that helps activate T-cells. In other words, ADA plays a role in turning on the immune response, not just by clearing toxic metabolites but by directly participating in cell-to-cell communication.
What Happens When ADA Is Missing
A genetic deficiency in ADA causes one of the most severe forms of immune deficiency, known as ADA-SCID (severe combined immunodeficiency). Affected individuals have less than 1% of normal ADA activity, and the toxic metabolite dATP accumulates to dramatically elevated levels in red blood cells. Without treatment, infants with this condition develop life-threatening infections within months of birth because they lack functional T-cells, B-cells, and natural killer cells.
Treatment options have expanded considerably. Enzyme replacement therapy uses a lab-made, modified version of ADA (sold as Revcovi) injected into muscle on a regular schedule. This restores ADA activity in the blood, clears toxic metabolites, and allows the immune system to gradually rebuild. Patients on enzyme replacement have achieved full immune reconstitution and sustained clinical improvement over years, though the therapy is expensive, requires ongoing injections, and demands continuous monitoring of ADA activity.
Gene therapy offers a more permanent solution. Early approaches used one type of viral vector to deliver a working copy of the ADA gene into a patient’s own blood stem cells, and these supported long-term survival and immune recovery. Newer approaches use lentiviral vectors, which are more efficient at inserting the gene and have shown more consistent immune reconstitution, with a higher percentage of patients able to stop supplemental antibody infusions entirely.
ADA as a Diagnostic Marker
Because immune cells produce ADA in large quantities when activated, measuring ADA levels in body fluids has become a practical diagnostic tool, particularly for tuberculosis. When TB bacteria infect the lining of the lungs, brain, or heart, the immune response drives ADA levels sharply upward in the surrounding fluid.
In pleural fluid (the fluid around the lungs), the standard cutoff is 40 U/L. Levels above that threshold strongly suggest tuberculous pleurisy rather than other causes of fluid buildup. In pericardial fluid (around the heart), normal levels sit below about 11 U/L. One case of confirmed TB pericarditis recorded a level of 118 U/L, more than ten times normal. In healthy adults, serum ADA typically ranges from about 7 to 15 IU/L.
These tests are especially valuable in parts of the world where TB is common and more advanced diagnostic tools may not be readily available. A simple ADA measurement on a fluid sample can guide treatment decisions quickly, though clinicians often combine it with other markers to improve accuracy.